Sun Pharma shelling out $485M to settle US antitrust case against generics giant
Sun Pharma has agreed to a big payout to settle claims of misconduct leveled against its Ranbaxy generics unit.
Just ahead of a trial over long-simmering allegations that Ranbaxy had schemed to muscle ahead of rivals and hit the market with 3 exclusive knockoffs of some of the biggest medicines of the time, Sun has agreed to shell out $485 million to settle the class action suit, without admitting to the charges.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.